<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00689299</url>
  </required_header>
  <id_info>
    <org_study_id>ALI002-08</org_study_id>
    <secondary_id>ALI002-08</secondary_id>
    <nct_id>NCT00689299</nct_id>
  </id_info>
  <brief_title>Phase 2 Study in Adults Sensitized to Cat</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study of Sublingual Immunotherapy (SLIT) in Adults Sensitized to the Standardized Allergenic Extract, Cat Hair (Felis Domesticus)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antigen Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Antigen Laboratories, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify an effective dose of allergen-specific immunotherapy
      for cat hair (Felis domesticus) administered by the oral/sublingual route.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a phase 2, randomized, double-blind, placebo-controlled, parallel groups study
      conducted in 3 centers in the US (NCT00689299). Study drug was sublingually dosed once daily
      as 0.15 mL of US standardized cat hair extract dosed either undiluted, as 1:10 dilution, or
      placebo. Target dose was obtained on Day 3 of dose titration escalating through 1:100 and
      1:10 dilutions on Day 1 and Day 2 in the high dose group or placebo and 1:100 dilutions in
      the low dose group. Treatment duration was 20 weeks. Adult (&gt;18 years) study subjects had
      positive history for cat allergy without asthma, positive skin test to cat allergen, absence
      of immunotherapy during the prior 2 years, and absence of other confounding baseline
      conditions. The primary outcome parameter was average Total Symptom Score (TSS) during a
      1-hour cat chamber exposure. TSS is the sum of 7 items rated from 0 - 3 (none to severe) for
      nasal symptoms (rhinorrhea, nasal congestion, nasal itching, and sneezing) and non-nasal
      symptoms (eye watering, eye itching, and itching palate/ ear/ throat).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Scores on a Scale (Average of Total Symptom Scores)</measure>
    <time_frame>20 weeks</time_frame>
    <description>Sum of individual symptoms scores, 7 items, 21 points maximum
Total Symptom Scores during environmental chamber exposures at week 20. The Total Symptom Score was defined as the sum of the scores from the following seven symptoms rated 0-3 (0=absent, 1=mild, 2= moderate, 3=severe): runny nose, sneezing, itching nose, nasal congestion, watery eyes, itchy eyes, and itchy ears/palate/throat.
Total Symptom score could range from 0-21; the lower the score, the more favorable the outcome. Each symptom parameter was graded by the study subject every 10 minutes for up to 60 minutes during the baseline (Day 0) and during the Week 20 environmental chamber exposures.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">167</enrollment>
  <condition>Allergy</condition>
  <arm_group>
    <arm_group_label>Dose Group C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standardized Allergenic Extract, Cat Hair (Felis domesticus) placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standardized Allergenic Extract, Cat Hair (Felis domesticus) 0.21 Units</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standardized Allergenic Extract, Cat Hair (Felis domesticus)2.1 units</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Standardized Allergenic Extract, Cat Hair</intervention_name>
    <description>Standardized Cat Hair Allergenic Extract sublingual drops</description>
    <arm_group_label>Dose Group A</arm_group_label>
    <arm_group_label>Dose Group B</arm_group_label>
    <other_name>Standardized Cat Hair Allergenic Extract</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Sublingual Drops</description>
    <arm_group_label>Dose Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients between ages of 18 and 55 years (inclusive).

          -  Written informed consent to participate in the study.

          -  Documented allergy to cat hair as demonstrated by a positive epicutaneous skin test
             (wheal &gt;3 mm) and symptoms of allergic rhinitis during exposure to cats.

          -  Female subjects of childbearing potential, defined as not surgically sterile or at
             least 2 years postmenopausal, must agree to use one of the following forms of
             contraception from screening through the 4 week follow-up period following the last
             dose of clinical trial: hormonal begun &gt;30 days prior to screening, barrier,
             intrauterine device or vasectomized partner (6 months minimum).

          -  No clinically significant abnormal findings on physical examination, with the
             exception of head, ears, eyes, nose, and throat (HEENT) findings consistent with
             allergic rhinitis, medical history, or clinical laboratory results during screening
             which would jeopardize the safety of the subject or impact validity of study results.

        Exclusion Criteria:

          -  Previous allergen immunotherapy (subcutaneous immunotherapy (SCIT), oral
             immunotherapy, sublingual immunotherapy (SLIT) or recombinant peptide) for cat within
             24 months of Screening Visit.

          -  History of severe allergic reaction requiring medical intervention.

          -  Intolerance of or severe allergic reaction to previous immunotherapy (SCIT, oral
             immunotherapy, SLIT, or recombinant peptide).

          -  Allergy to any of the non-antigen ingredients in the study drug formulation,
             including, but not limited to: Food, Drug and Cosmetic Act (FD&amp;C) Yellow #5, Red #40
             and Blue #1; sodium chloride; sodium bicarbonate; and glycerine.

          -  History of asthma requiring daily medication.

          -  Subjects receiving anti-IgE monoclonal antibodies.

          -  Congenital immune deficiency or acquired immune suppression. Causes of acquired immune
             suppression may include, but are not limited to, systemic illnesses such as malignancy
             and infection, the use of medications such as corticosteroids and chemotherapeutic
             agents, and radiation therapy.

          -  History of organ transplant, hematologic malignancy, autoimmune disease, myocardial
             infarction, or congestive heart failure.

          -  History of clinically significant gastrointestinal, renal, hepatic, neurologic,
             hematologic, endocrine, oncologic, pulmonary, psychiatric, or cardiovascular disease,
             or any other condition which, in the opinion of the Investigator, would jeopardize the
             safety of the subject or impact the validity of the study results.

          -  Inability or unwillingness to stop using drugs that may inhibit the wheal-and-flare
             reaction or rhinitic response prior to the study and for the duration of dosing
             clinical trial material (CTM), with the exception of protocol-specified rescue
             medications provided by the study site for use after Study Day 0. This includes, but
             is not limited to:

               -  Decongestants for 3 days prior to Study Day 0

               -  H1 antagonists (antihistamines) (oral, nasal or ocular) for 7 days prior to Study
                  Day 0

               -  Topical intranasal corticosteroids for 14 days prior to Study Day 0

               -  Cromolyn or nedocromil for 14 days prior to Study Day 0

               -  Systemic corticosteroids for 28 days prior to Study Day 0

               -  Tricyclic antidepressants for 28 days prior to Study Day 0

               -  Leukotriene modifiers for 7 days prior to study Day 0

          -  Inability or unwillingness to stop using drugs that may inhibit the ability to treat a
             severe allergic adverse event. This includes, but is not limited to: beta blockers
             such as atenolol (TenorminÂ®), metoprolol (LopressorÂ®, Toprol-XLÂ®) and propranolol
             (InderalÂ®, Inderal LAÂ®) for 14 days prior to Study Day 0 and for the duration of the
             study.

          -  Female subjects who are trying to conceive, are pregnant, or are lactating.

          -  Positive serum pregnancy test at screening or a positive human chorionic gonadotropin
             (HCG) urine test on Study Day 0 prior to administration of study drug for women of
             childbearing potential.

          -  Positive blood screen for human immunodeficiency virus (HIV), Hepatitis B surface
             antigen (HbSAg), or Hepatitis C.

          -  Forced Expiratory Volume in 1 second (FEV1) &lt;70% of the predicted value.

          -  History of alcohol or drug abuse within the year prior to the Screening Visit, or
             current evidence of substance dependence or abuse.

          -  Participation in a clinical trial or receipt of a non-FDA approved therapy within 30
             days prior to the Screening Visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert B. Berkowitz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allergen Response Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allergy &amp; Asthma Medical Group &amp; Research Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergen Response and Research Center</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2008</study_first_submitted>
  <study_first_submitted_qc>May 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2008</study_first_posted>
  <results_first_submitted>May 24, 2011</results_first_submitted>
  <results_first_submitted_qc>February 27, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 7, 2014</results_first_posted>
  <last_update_submitted>April 14, 2014</last_update_submitted>
  <last_update_submitted_qc>April 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sublingual Immunotherapy (SLIT)</keyword>
  <keyword>Non-seasonal allergic rhinitis</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Allergic rhinitis</keyword>
  <keyword>Cat</keyword>
  <keyword>Perennial allergy</keyword>
  <keyword>Non-seasonal allergy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Maintenance dose of 0.15 mL of liquid placebo administered as a daily oral liquid via sublingual route.</description>
        </group>
        <group group_id="P2">
          <title>2.1 Units Fel d 1</title>
          <description>Active Dose Group B
From a concentration of 14.0 Units/mL of Fel d 1, a maintenance dose of 0.15 mL (2.1 Units Fel d 1) was administered as a daily oral liquid via sublingual route.</description>
        </group>
        <group group_id="P3">
          <title>0.21 Units Fel d 1</title>
          <description>Active Dose Group A
From a concentration of 14.0 Units/mL of Fel d 1 diluted 1:10 v/v, a maintenance dose of 0.15 mL (0.21 Units Fel d 1) was administered as a daily oral liquid via sublingual route.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo - Dose Group C</description>
        </group>
        <group group_id="B2">
          <title>0.21 Units Fel d 1 Standardized Allergenic Extract, Cat Hair (</title>
          <description>Active Dose Group A</description>
        </group>
        <group group_id="B3">
          <title>2.1 Units Fel d 1 Standardized Allergenic Extract, Cat Hair (F</title>
          <description>Active Dose Group B</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
            <count group_id="B2" value="54"/>
            <count group_id="B3" value="57"/>
            <count group_id="B4" value="169"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34" spread="9"/>
                    <measurement group_id="B2" value="36" spread="8"/>
                    <measurement group_id="B3" value="33" spread="9"/>
                    <measurement group_id="B4" value="34.5" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Scores on a Scale (Average of Total Symptom Scores)</title>
        <description>Sum of individual symptoms scores, 7 items, 21 points maximum
Total Symptom Scores during environmental chamber exposures at week 20. The Total Symptom Score was defined as the sum of the scores from the following seven symptoms rated 0-3 (0=absent, 1=mild, 2= moderate, 3=severe): runny nose, sneezing, itching nose, nasal congestion, watery eyes, itchy eyes, and itchy ears/palate/throat.
Total Symptom score could range from 0-21; the lower the score, the more favorable the outcome. Each symptom parameter was graded by the study subject every 10 minutes for up to 60 minutes during the baseline (Day 0) and during the Week 20 environmental chamber exposures.</description>
        <time_frame>20 weeks</time_frame>
        <population>Modified Intent to Treat. All subjects with at least 1 symptom assessment during post treatment chamber exposure</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Dose Group C: placebo Standardized Allergenic Extract, Cat Hair (Felis domesticus)</description>
          </group>
          <group group_id="O2">
            <title>0.21 Units Standardized Allergenic Extract, Cat Hair</title>
            <description>Dose Group A</description>
          </group>
          <group group_id="O3">
            <title>2.1 Units Standardized Allergenic Extract, Cat Hair</title>
            <description>Dose Group B</description>
          </group>
        </group_list>
        <measure>
          <title>Scores on a Scale (Average of Total Symptom Scores)</title>
          <description>Sum of individual symptoms scores, 7 items, 21 points maximum
Total Symptom Scores during environmental chamber exposures at week 20. The Total Symptom Score was defined as the sum of the scores from the following seven symptoms rated 0-3 (0=absent, 1=mild, 2= moderate, 3=severe): runny nose, sneezing, itching nose, nasal congestion, watery eyes, itchy eyes, and itchy ears/palate/throat.
Total Symptom score could range from 0-21; the lower the score, the more favorable the outcome. Each symptom parameter was graded by the study subject every 10 minutes for up to 60 minutes during the baseline (Day 0) and during the Week 20 environmental chamber exposures.</description>
          <population>Modified Intent to Treat. All subjects with at least 1 symptom assessment during post treatment chamber exposure</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.02" spread="4.48"/>
                    <measurement group_id="O2" value="8.30" spread="5.14"/>
                    <measurement group_id="O3" value="7.87" spread="4.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ANOVA with baseline score as covariate</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>20 weeks treatment plus 30 days post treatment followup.</time_frame>
      <desc>Both SAEs reported in this study occurred in the 30 day post treatment followup, and were classified as not treatment related.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dose Group C</title>
          <description>placebo Standardized Allergenic Extract, Cat Hair (Felis domesticus)</description>
        </group>
        <group group_id="E2">
          <title>Dose Group A</title>
          <description>0.21 Units Standardized Allergenic Extract, Cat Hair (Felis domesticus)</description>
        </group>
        <group group_id="E3">
          <title>Dose Group B</title>
          <description>2.1 Units Standardized Allergenic Extract, Cat Hair (Felis domesticus)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Severe headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Oral pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Throat Irritation</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Nasal Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Adverse events: 41%, 58%, and 45% &gt; 5% in Group A, B, and C, respectively.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mark Hites</name_or_title>
      <organization>Greer Laboratories, Inc. for Antigen Laboratories, Inc.</organization>
      <phone>828-759-7548</phone>
      <email>mhites@greerlabs.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

